Merck Faces Challenges as Keytruda Patent Expiration Looms
Merck cuts 2025 revenue guidance and misses key drug sales targets in Q3, while preparing for Keytruda patent expiration and navigating tariff threats and China vaccine issues.
/ 921 items
#Healthcare↓
Novo Nordisk Makes $9 Billion Bid for Metsera, Topping Pfizer's Offer
Novo Nordisk offers $77.75/share for Metsera in $9B deal, beating Pfizer's bid. Two-step structure includes immediate $56.50 dividend + milestone payments.
Novo Nordisk Challenges Pfizer's $4.9B Deal for Obesity Startup Metsera
Novo Nordisk makes higher bid for Metsera to outbid Pfizer's $4.9B deal. Learn why this obesity drug startup is sparking a bidding war between pharmaceutical giants.
Intellia Therapeutics Stock Plunges on FDA Clinical Hold
Intellia Therapeutics (NTLA) shares drop 15% after FDA halts late-stage gene therapy trials following serious liver safety concerns in patient.
Guardant Health Beats Q3 Expectations, Raises Full-Year Revenue Guidance on Strong Oncology Growth
Guardant Health reports 39% revenue growth in Q3 2025, narrows losses, and increases full-year guidance to $965-970M driven by oncology expansion and Shield screening test adoption.
Wave Life Sciences (WVE-007): Why Experts See Big Potential for Weight Loss
Experts rate WVE-007 a Buy. It promises effective, safe weight loss, improves sugar use, and might need less frequent shots.